• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide.

作者信息

Dib Elie G, Antonarakis Emmanuel S, Wasco Matthew J, Powell Steven F

机构信息

Trinity Health/IHA Hematology Oncology Consultants, Ann Arbor, MI.

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

出版信息

Clin Genitourin Cancer. 2019 Apr;17(2):e365-e368. doi: 10.1016/j.clgc.2018.11.021. Epub 2018 Dec 6.

DOI:10.1016/j.clgc.2018.11.021
PMID:30587403
Abstract
摘要

相似文献

1
Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide.一名在接受恩杂鲁胺治疗期间病情进展的转移性去势抵抗性前列腺癌患者对帕博利珠单抗产生良好反应。
Clin Genitourin Cancer. 2019 Apr;17(2):e365-e368. doi: 10.1016/j.clgc.2018.11.021. Epub 2018 Dec 6.
2
Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer.在接受双相雄激素治疗和恩扎卢胺治疗的转移性去势抵抗性前列腺癌患者中，免疫检查点阻断的极端反应。
Prostate. 2020 Apr;80(5):407-411. doi: 10.1002/pros.23955. Epub 2020 Jan 23.
3
Germline DNA-repair Gene Mutations and Efficacy of Abiraterone or Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.胚系 DNA 修复基因突变与阿比特龙或恩杂鲁胺在转移性去势抵抗性前列腺癌患者中的疗效。
Eur Urol Focus. 2019 Sep;5(5):745-747. doi: 10.1016/j.euf.2019.02.011. Epub 2019 Feb 21.
4
Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.比较阿比特龙和恩杂鲁胺在转移性去势抵抗性前列腺癌中的临床疗效和安全性：系统评价和荟萃分析。
J Oncol Pharm Pract. 2021 Apr;27(3):614-622. doi: 10.1177/1078155220929414. Epub 2020 Jun 12.
5
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.种系 DNA 修复基因突变与一线接受阿比特龙和恩杂鲁胺治疗的转移性去势抵抗性前列腺癌男性的结局
Eur Urol. 2018 Aug;74(2):218-225. doi: 10.1016/j.eururo.2018.01.035. Epub 2018 Feb 10.
6
Metastatic castration-resistant prostate cancer: time for innovation.转移性去势抵抗性前列腺癌：创新之时
Future Oncol. 2015;11(1):91-106. doi: 10.2217/fon.14.145.
7
Is in vitro-acquired resistance to enzalutamide a useful model?体外获得性恩杂鲁胺耐药是一个有用的模型吗？
Future Oncol. 2014 Dec;10(16):2551-3. doi: 10.2217/fon.14.212.
8
Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.未经化疗的转移性去势抵抗性前列腺癌且基线前列腺特异性抗原低的男性患者使用恩扎卢胺与安慰剂治疗的临床结局对比。
J Urol. 2017 Dec;198(6):1324-1332. doi: 10.1016/j.juro.2017.07.071. Epub 2017 Jul 20.
9
Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.Wnt信号通路激活突变与去势抵抗性前列腺癌对一线阿比特龙和恩杂鲁胺的耐药性相关。
Eur Urol. 2020 Jan;77(1):14-21. doi: 10.1016/j.eururo.2019.05.032. Epub 2019 Jun 5.
10
A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer.一例依赖透析的去势抵抗性前列腺癌患者使用恩杂鲁胺的病例报告。
J Oncol Pharm Pract. 2018 Mar;24(2):143-145. doi: 10.1177/1078155216689381. Epub 2017 Feb 1.

引用本文的文献

1
Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration-resistant prostate cancer.一名晚期转移性去势抵抗性前列腺癌患者在假性进展后对帕博利珠单抗产生显著反应。
IJU Case Rep. 2022 Aug 2;5(6):442-445. doi: 10.1002/iju5.12508. eCollection 2022 Nov.